A once-daily pill originally developed for rheumatoid arthritis has produced some of the most dramatic hair regrowth results ever recorded in a clinical trial for alopecia areata. In two large international studies, up to 23 percent of patients with severe hair loss regained complete scalp coverage within six months, a finding that researchers say marks a significant step forward in treating this challenging autoimmune condition.
The results, published in JAMA Dermatology on August 12, 2026, come from the Phase 3 UP-AA clinical program, which enrolled nearly 1,400 participants across 248 sites in North America, Europe, and China. The drug, upadacitinib, is marketed by AbbVie under the brand name Rinvoq and belongs to a class of medications known as JAK inhibitors. The upadacitinib alopecia areata findings represent the largest Phase 3 dataset yet for this emerging treatment approach.
What the UP-AA Trial Discovered
The UP-AA program consisted of two replicate, randomized, double-blind, placebo-controlled trials: UP-AA1 and UP-AA2. Together they enrolled 1,399 participants, including 1,281 adults and 118 adolescents between the ages of 12 and 64. All participants had severe alopecia areata, defined as having lost at least 50 percent of their scalp hair. On average, volunteers had lost approximately 84 percent of their scalp hair at the start of the study.
Key design features of the trial included:
- Randomization: 2:2:1 ratio (15 mg: 30 mg: placebo)
- Primary endpoint: SALT score of 20 or less (at least 80 percent scalp coverage) at week 24
- Duration: 24-week double-blind period followed by a 28-week blinded extension (52 weeks total)
- Measurement tool: Severity of Alopecia Tool (SALT), which estimates the percentage of scalp hair present
- Baseline severity: Average SALT score of 83.9, meaning participants had lost approximately 84 percent of scalp hair
After 24 weeks, the results were striking:
- 15 mg dose: 45.2 percent in UP-AA1 and 44.6 percent in UP-AA2 achieved at least 80 percent scalp coverage
- 30 mg dose: 55.0 percent in UP-AA1 and 54.3 percent in UP-AA2 reached the same threshold
- Placebo: Only 1.5 percent in UP-AA1 and 3.4 percent in UP-AA2 showed comparable improvement
Beyond the primary endpoint, the data revealed even more impressive results at higher thresholds. At the 30 mg dose, approximately 46 percent of patients achieved 90 percent or greater scalp coverage. Between 13 and 23 percent of patients across both doses experienced complete scalp regrowth, meaning their SALT score dropped to zero. Notably, upadacitinib is the first JAK inhibitor to achieve complete scalp regrowth as a ranked secondary endpoint in a Phase 3 trial.
Improvements were not limited to the scalp. Most participants on the higher dose also experienced eyebrow and eyelash regrowth, and patients reported meaningful improvements in emotional well-being and social functioning. Responses continued to improve through the 28-week blinded extension period, suggesting that longer treatment may yield even better outcomes.
Understanding Alopecia Areata: An Autoimmune Attack on Hair
Alopecia areata is a chronic autoimmune disease in which the body’s immune system mistakenly targets hair follicles, causing hair loss on the scalp, face, and sometimes the entire body. The condition affects approximately 2 percent of the global population, with a lifetime risk estimated between 1.7 and 2.1 percent. In the United States alone, roughly 7 million people live with the condition.
The disease can range from small, patchy hair loss to complete baldness (alopecia totalis) or loss of all body hair (alopecia universalis).
Severity is measured using the SALT score, which estimates the percentage of scalp hair missing. A SALT score of 50 or higher is classified as severe, and these cases have historically been the most resistant to treatment.
Alopecia areata often begins in childhood or early adulthood, and its unpredictable nature can take a significant psychological toll. Common challenges reported by patients include:
- Anxiety and depression related to appearance changes
- Social withdrawal and avoidance of public situations
- Loss of self-confidence affecting work and relationships
- Frustration with the limited effectiveness of existing treatments
Until recently, treatment options for severe cases were limited, with corticosteroids and immunotherapy offering inconsistent results. Until recently, treatment options for severe cases were limited, with corticosteroids and immunotherapy offering inconsistent results.
How Upadacitinib Works: Blocking the JAK Pathway
Upadacitinib is a selective Janus kinase 1 (JAK1) inhibitor. JAK enzymes play a central role in the signaling pathways that regulate immune cell communication. In alopecia areata, overactive JAK signaling drives immune cells to attack hair follicles, interrupting the normal growth cycle and causing hair to fall out.
By selectively blocking JAK1, upadacitinib dampens this immune overreaction, allowing hair follicles to recover and resume producing hair. The drug is taken as a once-daily oral tablet with or without food.
What makes this finding particularly significant is the context. Upadacitinib was already approved by the U.S. Food and Drug Administration for several inflammatory conditions, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, and psoriatic arthritis. Researchers hypothesized that the same mechanism used in immune-inhibiting therapies for conditions like eczema could also interrupt the autoimmune attack responsible for alopecia areata, and the UP-AA trials confirmed that hypothesis on a large scale.
How Upadacitinib Compares to Other Alopecia Treatments
Upadacitinib is not the first JAK inhibitor to show promise against alopecia areata. Three other drugs in the same class have already received FDA approval for the condition in the United States. However, the UP-AA trial results suggest that upadacitinib may offer superior efficacy.
The table below compares the key efficacy data from clinical trials of JAK inhibitors approved or under review for severe alopecia areata. It is important to note that these trials differed in design, duration, patient populations, and endpoints, so the figures should be interpreted as approximate benchmarks rather than direct head-to-head comparisons.
| Drug (Brand Name) | Manufacturer | Mechanism | 80% Scalp Coverage | Trial Duration | Age Approved |
|---|---|---|---|---|---|
| Upadacitinib (Rinvoq) | AbbVie | Selective JAK1 | 45 to 55% | 24 weeks | 12+ (EU); FDA pending |
| Baricitinib (Olumiant) | Eli Lilly | JAK1/JAK2 | 35 to 39% | 36 weeks | 18+ |
| Deuruxolitinib (Leqselvi) | Sun Pharma | Selective JAK1/JAK2 | 31% | 24 weeks | 18+ |
| Ritlecitinib (Litfulo) | Pfizer | JAK3/TEC | 23% | 24 weeks | 12+ |
At the higher 30 mg dose, upadacitinib achieved 80 percent scalp coverage in 55 percent of patients, outperforming baricitinib (35 to 39 percent), deuruxolitinib (31 percent), and ritlecitinib (23 percent) by a meaningful margin. For context, an earlier JAK inhibitor, baricitinib, restored hair in roughly a third of alopecia patients when it was first studied in 2022, making the upadacitinib results a notable step forward. The complete regrowth rate of up to 23 percent at the higher dose also stands out, as achieving total hair restoration remains rare across all available treatments.
Another distinguishing factor is the speed of response. Researchers noted visible improvement in some participants as early as eight weeks into treatment, with results continuing to improve through the 52-week extension period.
Safety Profile and Side Effects to Know
As with all JAK inhibitors, upadacitinib carries important safety considerations. The drug belongs to a class that the FDA has required to carry boxed warnings about potential risks of serious infections, cardiovascular events, blood clots, cancer, and death. These warnings are based primarily on data from rheumatoid arthritis patients treated with higher doses over longer periods, and the risk profile may differ in younger, otherwise healthy alopecia areata patients.
During the 24-week placebo-controlled period of the UP-AA trials, the most common treatment-emergent adverse events reported in more than 5 percent of patients in any group included:
- Upper respiratory tract infections (most common across all groups)
- Acne (a known class effect of JAK inhibitors)
- Elevated blood creatine phosphokinase (a muscle enzyme marker)
- Nasopharyngitis (common cold symptoms)
The table below summarizes the overall safety data from the 24-week placebo-controlled period:
| Safety Measure | Upadacitinib 15 mg | Upadacitinib 30 mg | Placebo |
|---|---|---|---|
| Any adverse event | 62.7% | 67.1% | 57.1% |
| Serious adverse events | 1.6% | 2.3% | 0.4% |
| Serious infections | 0.7% | 1.0% | 0% |
| Discontinuations due to adverse events | 0.7% | 1.4% | 0% |
| Major cardiovascular events | 0 | 0 | 0 |
| Malignancies | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 |
Serious adverse events occurred in 1.6 percent of patients on the 15 mg dose and 2.3 percent on the 30 mg dose, compared with 0.4 percent on placebo. Serious infections were reported in 0.7 percent (15 mg) and 1.0 percent (30 mg) of patients. There were no adjudicated major adverse cardiovascular events, malignancies, or deaths during the trial. One venous thromboembolism was reported in a patient on the 15 mg dose who had multiple pre-existing risk factors.
Herpes virus reactivation, including shingles, is a known risk with JAK inhibitors, as documented in a systematic review of JAK inhibitor safety in alopecia areata patients. Clinicians can mitigate this by ensuring patients receive the recombinant zoster vaccine (Shingrix) before or during treatment. Regular monitoring of liver function, lipid levels, and blood counts is recommended during therapy.
The safety profile observed in the UP-AA trials was consistent with upadacitinib’s established profile across its other approved indications, and no new safety signals were identified.
FDA Approval Status: What Patients Should Know
As of August 2026, upadacitinib’s regulatory status for alopecia areata differs significantly between the United States and Europe.
The European Commission approved upadacitinib for severe alopecia areata in adults and adolescents aged 12 and older on July 29, 2026, making it the latest systemic option available to European clinicians. Both the 15 mg and 30 mg doses were approved.
In the United States, AbbVie submitted a supplemental New Drug Application (sNDA) to the FDA on April 28, 2026. The agency has not announced a target action date, but standard review timelines suggest a decision could come in early 2027. If approved, upadacitinib would become the fourth JAK inhibitor cleared by the FDA for severe alopecia areata, joining baricitinib, ritlecitinib, and deuruxolitinib.
In the meantime, U.S. physicians may prescribe upadacitinib off-label for alopecia areata, though insurance coverage for this use varies. Patients interested in the treatment should discuss options with a dermatologist, who can evaluate whether the potential benefits outweigh the risks based on individual health history.
What This Means for Alopecia Areata Treatment
The UP-AA results represent more than just another treatment option. For a condition that has long lacked effective therapies, the finding that more than half of patients on the higher dose achieved substantial hair regrowth, and that nearly one in four experienced complete restoration, marks a meaningful shift in what patients and physicians can expect.
The data also reinforce a broader trend in dermatology: repurposing drugs developed for one immune-mediated condition to treat others that share underlying mechanisms. Researchers have also explored stem cell topical solutions and red light therapy as complementary approaches to hair restoration, though systemic JAK inhibitors currently show the strongest results for autoimmune-driven hair loss. Upadacitinib’s journey from rheumatoid arthritis to alopecia areata illustrates how understanding the immune pathways driving different diseases can open unexpected therapeutic doors.
As the FDA reviews AbbVie’s application and longer-term safety and efficacy data continue to accumulate, the coming months will be critical for determining how widely upadacitinib is adopted for alopecia areata. For the millions of people living with severe hair loss, the prospect of a once-daily pill that can restore not just hair but confidence and quality of life represents genuine progress.
Frequently Asked Questions
Does Rinvoq treat alopecia areata?
Yes. In two Phase 3 clinical trials published in JAMA Dermatology, upadacitinib (brand name Rinvoq) demonstrated significant efficacy in treating severe alopecia areata. Between 45 and 55 percent of patients achieved at least 80 percent scalp hair coverage within 24 weeks, and up to 23 percent experienced complete regrowth. The drug is approved for this indication in the European Union and is under FDA review in the United States.
What is the best drug for alopecia areata?
The best drug depends on individual factors, including disease severity, age, medical history, and treatment response. Four JAK inhibitors have shown efficacy in clinical trials: upadacitinib, baricitinib, deuruxolitinib, and ritlecitinib. Among these, upadacitinib has produced the highest response rates in Phase 3 trials, with 55 percent of patients on the 30 mg dose achieving 80 percent or greater scalp coverage. However, treatment decisions should be made in consultation with a dermatologist who can evaluate the full risk-benefit profile for each patient.
Is upadacitinib a high-risk drug?
Upadacitinib carries an FDA boxed warning, as do all JAK inhibitors, regarding potential risks of serious infections, cardiovascular events, blood clots, cancer, and death. These warnings are based primarily on data from older rheumatoid arthritis patients treated at higher doses. In the UP-AA alopecia areata trials, the safety profile was generally consistent with other approved uses, with mostly mild side effects such as acne and upper respiratory infections. No major cardiovascular events, cancers, or deaths were reported. Patients should discuss their individual risk factors with their doctor.
Can upadacitinib cause hair loss?
Paradoxically, there have been rare case reports of alopecia areata developing in patients taking upadacitinib for other conditions such as atopic dermatitis. However, these are isolated cases and do not reflect the drug’s overall effect in alopecia areata patients, where the large-scale clinical trial data clearly demonstrate significant hair regrowth.
How long does it take for upadacitinib to regrow hair?
In the UP-AA trials, some patients began showing visible hair regrowth as early as eight weeks after starting treatment. The primary endpoint was measured at 24 weeks (approximately six months), at which point 45 to 55 percent of patients had achieved at least 80 percent scalp coverage. Responses continued to improve through the 52-week extension period, suggesting that longer treatment may lead to even better results.
